Comparison of Efficacy Between Combination of Amitriptyline-propranolol and Pizotifen for Migraine Prophylaxis.
- Disease/Condition
- Migraine
- Drug/Device/Intervention
- Pizotifen
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Location
- Dhaka, Bangladesh
- Phase
- Phase 2
- Start date
- Mar 19, 2023
- End date
- Jan 15, 2024
- Enrollment
- 140 participants
Frequency of headache per month,Duration of headache per month,Severity of headache
The goal of this clinical trial is to compare efficacy and observe common adverse effects of
 a combination of amitriptyline-propranolol and pizotifen as prophylactic treatments for
 migraine. The main question it aims to answer is:
 
 • Does pizotifen more effective than the combination of amitriptyline-propranolol in migraine
 prophylaxis?
 
 Participants will be asked to :
 
 - Maintain the provided headache diary accordingly
 
 - Take supplied drugs as described during clinical visits
 
 - Contact principle investigator if there is any issues regarding drug use and/or their
 adverse effects
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06158230
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06158230 through Pure Global AI's free database. This Phase 2 trial is sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh and is currently Recruitment Completed. The study focuses on Migraine. Target enrollment is 140 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.